(Total Views: 90)
Posted On: 03/25/2025 5:14:36 PM
Post# of 373
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Phase 2 Results for Berubicin in Glioblastoma Trial
CNS Pharmaceuticals (NASDAQ: CNSP) announced results from its Phase 2 clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM). While the study did not meet its primary endpoint of statistically significant improvement in overall survival compared to standard-of-care Lomustine, Berubicin showed comparable results across key clinical outcomes, including in patients with poor tumor markers. Importantly, no cardiotoxicity was observed, a major concern with other anthracyclines, and the safety profile remained favorable. The company plans to continue analysis and explore further development of Berubicin and its pipeline candidate TPI 287 for CNS malignancies.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP) announced results from its Phase 2 clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM). While the study did not meet its primary endpoint of statistically significant improvement in overall survival compared to standard-of-care Lomustine, Berubicin showed comparable results across key clinical outcomes, including in patients with poor tumor markers. Importantly, no cardiotoxicity was observed, a major concern with other anthracyclines, and the safety profile remained favorable. The company plans to continue analysis and explore further development of Berubicin and its pipeline candidate TPI 287 for CNS malignancies.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
